Drugs / Tiratricol
Tiratricol
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Emcitate | — | 2025-02-12 | europa.eu ↗ |
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03783988 | Jan → Jun 2019 | skin atrophy | Trophea Development AB | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02396459 | Dec 2020 → Jul 2027 expected | Allan-Herndon-Dudley syndrome | Rare Thyroid Therapeutics International AB | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02060474 | Oct 2014 → Jun 2018 | Allan-Herndon-Dudley syndrome | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05579327 | Jul 2023 → Jul 2025 | Allan-Herndon-Dudley syndrome, disorder of metabolite absorption and transport | Rare Thyroid Therapeutics International AB | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05911399 | — | Allan-Herndon-Dudley syndrome, disorder of metabolite absorption and transport | Rare Thyroid Therapeutics International AB | Available | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tiratricol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02396459 ↗ |
| Known as | 3,3',5-tri-iodothyroacetic acid | “Treatment that safely alleviates peripheral thyrotoxicosis and reverses cerebral hypothyroidism is not yet available. We aimed to investigate the effects of treatment with the...” PMID 31377265 ↗ Jul 20191“Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous...” NCT05911399 ↗ |
| Known as | 3,5,3'-triiodothyroacetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL41632 ↗ |
| Known as | Levothyroxine sodium impurity, triiodothyroacetic acid, or t3-acetic acid- | ChEMBL registry synonym — accepted as the source's own label CHEMBL41632 ↗ |
| Known as | NSC-759294 | ChEMBL registry synonym — accepted as the source's own label CHEMBL41632 ↗ |
| Known as | T3-acetic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL41632 ↗ |
| Known as | Tiracana | ChEMBL registry synonym — accepted as the source's own label CHEMBL41632 ↗ |
| Known as | TRIAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03783988 ↗ |
| Known as | triiodothyroacetic acid | “The new topical gel contains dehydroepiandrosterone (DHEA) and triiodothyroacetic acid (TRIAC)” NCT03783988 ↗ |
| Modality | Small molecule | “Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.” NCT02060474 ↗ |
| Route | Oral | “effectiveness and safety of oral Triac” PMID 31377265 ↗ Jul 2019 |